ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0315

The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab

Evgeny Nasonov1, Eugen Feist2, Michael Luggen3, Sergey Yakushin4, Daria Bukhanova5, Alina Egorova6, Sergey Grishin6, Mikhail Samsonov5 and Josef Smolen7, 1V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 2Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, 3University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, 4Ryazan State Medical University named after academician I.P. Pavlov, Ryazan, Russia, 5R-Pharm JSC, Moscow, Russia, 6R-Pharm, Moscow, Russia, 7Medical University of Vienna, Vienna, Austria

Meeting: ACR Convergence 2022

Keywords: Anti-TNF Drugs, Biologicals, Comorbidity, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Treatment Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Comorbid conditions may affect efficacy of treatment in patients with rheumatoid arthritis (RA). The aim of this analysis was to evaluate the impact of comorbidity burden on the efficacy of IL-6 inhibitor olokizumab (OKZ) and TNF-α inhibitor adalimumab (ADA) in the CREDO-2 clinical trial cohort of patients with active rheumatoid arthritis (RA).

Methods: Patients in the double-blind RCT (NCT02760407, CREDO-2) received OKZ 64 mg once every 2 weeks (q2w) or 4 weeks (q4w), or ADA 40mg q2w for 24 weeks.

To assess the impact of comorbid conditions on efficacy, outcomes were stratified by patients with Low Charlson Comorbidity Index (CCI = 1; RA only) vs High (CCI ≥ 2; RA and at least 1 comorbidity). Age-points in CCI were excluded since the aim of the analysis was the assessment of comorbidity burden, rather than the mortality prediction.

The comparison of outcomes between the Low and the High CCI groups was performed using χ2-test in unadjusted analysis, and logistic regression in adjusted analysis. Baseline characteristics with an absolute standardized difference > 0.1 were identified as covariates for adjusted comparison. The impact of comorbidity was investigated separately for OKZ and ADA.

The following efficacy parameters were analyzed at Week 12 and Week 24 after the treatment initiation for both ADA and OKZ groups: American College of Rheumatology 20 (ACR20) and 50 (ACR50) responses, proportion of patients achieved Simplified Disease Activity Index (SDAI) ≤ 3.3, Clinical Disease Activity Index (CDAI) ≤ 2.8 and ≤ 10, and Disease Activity Score 28-joint count – C-reactive protein (DAS28(CRP)) ≤ 3.2.

Results: A total of 1402 patients with RA were included to the analysis: 940 patients treated with OKZ 64 mg q2w or q4w (701 (74,6%) with Low CCI and 239 (25,4%) with High CCI) and 462 patients treated with ADA 40mg q2w (352 (76,2%) with Low CCI and 110 (23,8%) with High CCI). All the patients received background MTX therapy.

Gender; age; BMI; smoking status; baseline HAQ Disability Index Score and level of CRP were considered as covariates for the analysis. Additionally, race and alcohol consumption status parameters and duration of RA were considered as covariates for OKZ and ADA analysis, respectively.

There was no difference in efficacy results between OKZ-treated groups of RA patients with and without comorbid conditions during the study (Table 1), except the achievement of SDAI ≤ 3.3 at Week 24, which was observed more frequently in the Low CCI group.

The presence of comorbid conditions affected the efficacy of ADA therapy. In the group of High CCI, the proportions of patients who achieved ACR 20 response at Week 12, ACR 50 response (Weeks 12 and 24), SDAI ≤ 3.3 (Weeks 12 and 24), CDAI ≤ 2.8 (Week 24) and CDAI ≤ 10 (Week 24) were significantly lower in comparison with the group of Low CCI (Table 2).

Conclusion: In general, there are no differences in efficacy parameters between the groups of RA patients with High and Low comorbidity burden treated with OKZ. In the group of RA patients treated with ADA, presence of at least one additional comorbid condition (high CCI) was associated with significantly lower treatment efficacy.

Supporting image 1

Abbreviations: ACR 20, 20% improvement in the American College of Rheumatology criteria; ACR 50, 50% improvement in the American College of Rheumatology criteria; CDAI, Clinical Disease Activity Index; CI, Confidence interval; DAS28 (CRP), Disease Activity Score 28-joint count based on C-reactive protein; SDAI, Simplified Disease Activity Index. Bold font of p-values indicates statistical significance.

Supporting image 2

Abbreviations: ACR 20, 20% improvement in the American College of Rheumatology criteria; ACR 50, 50% improvement in the American College of Rheumatology criteria; CDAI, Clinical Disease Activity Index; CI, Confidence interval; DAS28 (CRP), Disease Activity Score 28-joint count based on C-reactive protein; SDAI, Simplified Disease Activity Index. Bold font of p-values indicates statistical significance.


Disclosures: E. Nasonov, AbbVie/Abbott, Eli Lilly, Janssen, Novartis, Pfizer, R-Pharm; E. Feist, AbbVie, Lilly, Galapagos, Novartis, Pfizer, Roche, SOBI, BMS, MSD; M. Luggen, AbbVie/Abbott, Biogen, GlaxoSmithKlein(GSK), Eli Lilly, R-Pharm, Sun Pharm, UCB; S. Yakushin, Servier, Bayer, Sanofi, Behringer, Gedeon Richter, AstraZeneca, Gilead, Gexal AG, Novartis, Genzyme Corp., Roche, GlaxoSmithKlein(GSK), Eli Lilly, R-Pharm; D. Bukhanova, R-Pharm; A. Egorova, R-Pharm; S. Grishin, R-Pharm; M. Samsonov, R-Pharm; J. Smolen, AbbVie, AstraZeneca, Eli Lilly, Novartis, Amgen, Bristol Myers Squibb, Galapagos-Gilead, Janssen, Merck-Sharp-Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, UCB.

To cite this abstract in AMA style:

Nasonov E, Feist E, Luggen M, Yakushin S, Bukhanova D, Egorova A, Grishin S, Samsonov M, Smolen J. The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-comorbidities-on-the-efficacy-of-il-6-inhibitor-olokizumab-compared-to-adalimumab/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-comorbidities-on-the-efficacy-of-il-6-inhibitor-olokizumab-compared-to-adalimumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology